Drug Profile
Osimertinib - AstraZeneca
Alternative Names: [11C]AZD9291; [11C]osimertinib; ADAURA; AZD-9291; Mereletinib; TAGRISSO; TagrissoLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly and Company; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Genprex; HUTCHMED; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Princess Margaret Hospital (University of Toronto); Singapore Clinical Research Institute; Sunnybrook Health Sciences Centre; University of California at San Francisco
- Class Acrylamides; Amides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Cancer; Solid tumours
- Phase II Adenocarcinoma; Glioblastoma; Meningeal carcinomatosis
Most Recent Events
- 27 Mar 2024 Efficacy data from a phase III FLAURA2 trial in Non-small cell lung cancer released by AstraZeneca
- 18 Feb 2024 Efficacy and adverse events data from the phase III LAURA trial in Non-small cell lung cancer released by AstraZeneca
- 17 Feb 2024 Preregistration for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia (PO)